Literature DB >> 27109623

The CRF1 Antagonist Verucerfont in Anxious Alcohol-Dependent Women: Translation of Neuroendocrine, But not of Anti-Craving Effects.

Melanie L Schwandt1, Carlos R Cortes1,2, Laura E Kwako1, David T George1, Reza Momenan1, Rajita Sinha3, Dimitri E Grigoriadis4, Emilio Merlo Pich5, Lorenzo Leggio6, Markus Heilig1,2.   

Abstract

Blockade of corticotropin-releasing factor receptor 1 (CRF1) suppresses stress-induced alcohol seeking in rodents, but clinical translation remains. Here, we first showed that the CRF1 antagonist verucerfont potently blocks hypothalamic-pituitary adrenal (HPA) axis activation in adrenalectomized rats. We then evaluated verucerfont for its ability to block HPA axis activation and reduce stress-induced alcohol craving in alcohol-dependent patients. Anxious, alcohol-dependent women (age 21-65 years, n=39) were admitted to the NIH Clinical Center and completed withdrawal treatment before enrollment if needed. One-week single-blind placebo was followed by randomized double-blind verucerfont (350 mg per day) or placebo for 3 weeks. Verucerfont effects on the HPA axis were evaluated using the dexamethasone-CRF test. Craving was evaluated using two established protocols, one that combines a social stressor with physical alcohol cue exposure, and one that uses guided imagery to present personalized stress, alcohol, or neutral stimuli. An fMRI session examined brain responses to negative affective stimuli and alcohol cues. In contrast to our recent observations with another CRF1 antagonist, pexacerfont, verucerfont potently blocked the HPA axis response to the dexamethasone-CRF test, but left alcohol craving unaffected. Right amygdala responses to negative affective stimuli were significantly attenuated by verucerfont, but responses to alcohol-associated stimuli were increased in some brain regions, including left insula. Discontinuation rates were significantly higher in the verucerfont group. Our findings provide the first translational evidence that CRF1 antagonists with slow receptor dissociation kinetics may have increased efficacy to dampen HPA axis responses. The findings do not support a clinical efficacy of CRF1 blockade in stress-induced alcohol craving and relapse.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27109623      PMCID: PMC5061889          DOI: 10.1038/npp.2016.61

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  45 in total

Review 1.  Pharmacogenetic approaches to the treatment of alcohol addiction.

Authors:  Markus Heilig; David Goldman; Wade Berrettini; Charles P O'Brien
Journal:  Nat Rev Neurosci       Date:  2011-10-20       Impact factor: 34.870

2.  Exposure to negative emotional cues and alcohol cue reactivity with alcoholics: a preliminary investigation.

Authors:  P R Stasiewicz; S B Gulliver; C M Bradizza; D J Rohsenow; R Torrisi; P M Monti
Journal:  Behav Res Ther       Date:  1997-12

3.  The 'Trier Social Stress Test'--a tool for investigating psychobiological stress responses in a laboratory setting.

Authors:  C Kirschbaum; K M Pirke; D H Hellhammer
Journal:  Neuropsychobiology       Date:  1993       Impact factor: 2.328

4.  Constrained corticotropin releasing factor antagonists (astressin analogues) with long duration of action in the rat.

Authors:  J E Rivier; D A Kirby; S L Lahrichi; A Corrigan; W W Vale; C L Rivier
Journal:  J Med Chem       Date:  1999-08-12       Impact factor: 7.446

5.  The CRH1 antagonist GSK561679 increases human fear but not anxiety as assessed by startle.

Authors:  Christian Grillon; Elizabeth Hale; Lynne Lieberman; Andrew Davis; Daniel S Pine; Monique Ernst
Journal:  Neuropsychopharmacology       Date:  2015-03-13       Impact factor: 7.853

6.  Psychometric properties of the Penn Alcohol Craving Scale.

Authors:  B A Flannery; J R Volpicelli; H M Pettinati
Journal:  Alcohol Clin Exp Res       Date:  1999-08       Impact factor: 3.455

7.  Additive effect of stress and drug cues on reinstatement of ethanol seeking: exacerbation by history of dependence and role of concurrent activation of corticotropin-releasing factor and opioid mechanisms.

Authors:  Xiu Liu; Friedbert Weiss
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

8.  Neurokinin 1 receptor antagonism as a possible therapy for alcoholism.

Authors:  David T George; Jodi Gilman; Jacqueline Hersh; Annika Thorsell; David Herion; Christopher Geyer; Xiaomei Peng; William Kielbasa; Robert Rawlings; John E Brandt; Donald R Gehlert; Johannes T Tauscher; Stephen P Hunt; Daniel Hommer; Markus Heilig
Journal:  Science       Date:  2008-02-14       Impact factor: 47.728

Review 9.  Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.

Authors:  Markus Heilig; Mark Egli
Journal:  Pharmacol Ther       Date:  2006-03-20       Impact factor: 12.310

Review 10.  Neurobiology of relapse to alcohol in rats.

Authors:  A Lê; Y Shaham
Journal:  Pharmacol Ther       Date:  2002 Apr-May       Impact factor: 12.310

View more
  66 in total

Review 1.  Modeling anxiety in healthy humans: a key intermediate bridge between basic and clinical sciences.

Authors:  Christian Grillon; Oliver J Robinson; Brian Cornwell; Monique Ernst
Journal:  Neuropsychopharmacology       Date:  2019-06-21       Impact factor: 7.853

2.  Intermittent Access to Ethanol Induces Escalated Alcohol Consumption in Primates.

Authors:  S G Lindell; M L Schwandt; S J Suomi; K C Rice; M Heilig; C S Barr
Journal:  J Addict Behav Ther Rehabil       Date:  2017-04-07

Review 3.  Alcohol, stress, and glucocorticoids: From risk to dependence and relapse in alcohol use disorders.

Authors:  Sara K Blaine; Rajita Sinha
Journal:  Neuropharmacology       Date:  2017-02-01       Impact factor: 5.250

Review 4.  Time to connect: bringing social context into addiction neuroscience.

Authors:  Markus Heilig; David H Epstein; Michael A Nader; Yavin Shaham
Journal:  Nat Rev Neurosci       Date:  2016-06-09       Impact factor: 34.870

Review 5.  Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development.

Authors:  George F Koob
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

Review 6.  Don't stress about CRF: assessing the translational failures of CRF1antagonists.

Authors:  Samantha R Spierling; Eric P Zorrilla
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

Review 7.  Modulation of drug choice by extended drug access and withdrawal in rhesus monkeys: Implications for negative reinforcement as a driver of addiction and target for medications development.

Authors:  S Stevens Negus; Matthew L Banks
Journal:  Pharmacol Biochem Behav       Date:  2017-04-22       Impact factor: 3.533

8.  The effects of a repeated dose of a recombinant humanized anti-cocaine monoclonal antibody on cocaine self-administration in rats.

Authors:  Hanna N Wetzel; Vladimir L Tsibulsky; Andrew B Norman
Journal:  Drug Alcohol Depend       Date:  2016-10-06       Impact factor: 4.492

9.  Differential sensitivity of alcohol drinking and partner preference to a CRFR1 antagonist in prairie voles and mice.

Authors:  Sheena Potretzke; Meridith T Robins; Andrey E Ryabinin
Journal:  Horm Behav       Date:  2020-01-13       Impact factor: 3.587

Review 10.  Corticotropin-Releasing Factor (CRF) Neurocircuitry and Neuropharmacology in Alcohol Drinking.

Authors:  Allyson L Schreiber; Nicholas W Gilpin
Journal:  Handb Exp Pharmacol       Date:  2018
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.